Bachurski, P., Chmiel, G., Kalinowski, P., Międlar, M., Muda, M., Pacek, S., … Zarański, B. (2026). Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025). Quality in Sport, 51, 68252. https://doi.org/10.12775/QS.2026.51.68252